Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 337

1.

Treatment of psoriasis and psoriatic arthritis.

Papoutsaki M, Costanzo A.

BioDrugs. 2013 Jan;27 Suppl 1:3-12. doi: 10.1007/BF03325637. Review.

PMID:
23990277
2.

Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial.

Ritchlin C, Rahman P, Kavanaugh A, McInnes IB, Puig L, Li S, Wang Y, Shen YK, Doyle MK, Mendelsohn AM, Gottlieb AB; PSUMMIT 2 Study Group..

Ann Rheum Dis. 2014 Jun;73(6):990-9. doi: 10.1136/annrheumdis-2013-204655. Epub 2014 Jan 30.

3.

Current status and new developments in the treatment of psoriasis and psoriatic arthritis with biological agents.

Weger W.

Br J Pharmacol. 2010 Jun;160(4):810-20. doi: 10.1111/j.1476-5381.2010.00702.x. Review.

4.

Infliximab in psoriasis and psoriatic arthritis.

Papoutsaki M, Osório F, Morais P, Torres T, Magina S, Chimenti S, Costanzo A.

BioDrugs. 2013 Jan;27 Suppl 1:13-23. doi: 10.1007/BF03325638. Review.

PMID:
23990278
5.

Therapeutic strategies in psoriasis patients with psoriatic arthritis: focus on new agents.

Gan EY, Chong WS, Tey HL.

BioDrugs. 2013 Aug;27(4):359-73. doi: 10.1007/s40259-013-0025-6. Review.

PMID:
23580094
6.

TNF-α in a molecularly targeted therapy of psoriasis and psoriatic arthritis.

Wcisło-Dziadecka D, Zbiciak-Nylec M, Brzezińska-Wcisło L, Mazurek U.

Postgrad Med J. 2016 Mar;92(1085):172-8. doi: 10.1136/postgradmedj-2015-133419. Epub 2015 Dec 30. Review.

PMID:
26719452
7.

Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.

Rodgers M, Epstein D, Bojke L, Yang H, Craig D, Fonseca T, Myers L, Bruce I, Chalmers R, Bujkiewicz S, Lai M, Cooper N, Abrams K, Spiegelhalter D, Sutton A, Sculpher M, Woolacott N.

Health Technol Assess. 2011 Feb;15(10):i-xxi, 1-329. doi: 10.3310/hta15100. Review.

8.

Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.

Woolacott N, Bravo Vergel Y, Hawkins N, Kainth A, Khadjesari Z, Misso K, Light K, Asseburg C, Palmer S, Claxton K, Bruce I, Sculpher M, Riemsma R.

Health Technol Assess. 2006 Sep;10(31):iii-iv, xiii-xvi, 1-239. Review.

9.

Treatment of nail psoriasis with TNF-α or IL12/23 inhibitors.

Jemec GB, Ibler KS.

J Drugs Dermatol. 2012 Aug;11(8):939-42. Review.

PMID:
22859238
10.

TNF alpha inhibitors in the treatment of psoriasis and psoriatic arthritis.

Tobin AM, Kirby B.

BioDrugs. 2005;19(1):47-57. Review.

PMID:
15691217
11.

Costs of tumor necrosis factor blockers per treated patient using real-world drug data in a managed care population.

Schabert VF, Watson C, Joseph GJ, Iversen P, Burudpakdee C, Harrison DJ.

J Manag Care Pharm. 2013 Oct;19(8):621-30.

12.
13.

[Biologic therapies in the treatment of psoriasis].

Farhi D, Dupin N.

Presse Med. 2009 May;38(5):832-43. doi: 10.1016/j.lpm.2008.07.023. Epub 2009 Mar 17. French.

PMID:
19282134
14.

Biological agents in the treatment of psoriasis.

Tzu J, Krulig E, Cardenas V, Kerdel FA.

G Ital Dermatol Venereol. 2008 Oct;143(5):315-27. Review.

PMID:
18833073
15.

[Novel biologics in treatment of psoriatic arthritis].

ZHOU J, ZHENG M.

Zhejiang Da Xue Xue Bao Yi Xue Ban. 2009 Jul;38(4):404-8. Review. Chinese.

PMID:
19693980
16.

Combination of antitumour necrosis factor-α and anti-interleukin-12/23 antibodies in refractory psoriasis and psoriatic arthritis: a long-term case-series observational study.

Gniadecki R, Bang B, Sand C.

Br J Dermatol. 2016 May;174(5):1145-6. doi: 10.1111/bjd.14270. Epub 2016 May 4. No abstract available.

PMID:
26522308
17.

Comparative effectiveness of less commonly used systemic monotherapies and common combination therapies for moderate to severe psoriasis in the clinical setting.

Takeshita J, Wang S, Shin DB, Callis Duffin K, Krueger GG, Kalb RE, Weisman JD, Sperber BR, Stierstorfer MB, Brod BA, Schleicher SM, Robertson AD, Linn KA, Shinohara RT, Troxel AB, Van Voorhees AS, Gelfand JM.

J Am Acad Dermatol. 2014 Dec;71(6):1167-75. doi: 10.1016/j.jaad.2014.08.003. Epub 2014 Sep 24.

18.

Multiple lentigines in areas of resolving psoriatic plaques after ustekinumab therapy.

Gutiérrez-González E, Batalla A, de la Mano D.

Dermatol Online J. 2014 Apr 16;20(4):22338.

19.

[New systemic treatments for psoriasis: etanercept, infliximab, adalimumab, efalizumab and alefacept].

Bos WE, Thio HB, Neumann HA, van der Fits L, Prens EP.

Ned Tijdschr Geneeskd. 2006 May 13;150(19):1065-70. Review. Dutch.

PMID:
16733982
20.

A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.

Chen YF, Jobanputra P, Barton P, Jowett S, Bryan S, Clark W, Fry-Smith A, Burls A.

Health Technol Assess. 2006 Nov;10(42):iii-iv, xi-xiii, 1-229. Review.

Supplemental Content

Support Center